# National Research Corporation (NRC) Stock Analysis: A High ROE Healthcare Play with a Healthy Dividend Yield

- Link: https://www.directorstalkinterviews.com/national-research-corporation-nrc-stock-analysis-a-high-roe-healthcare-play-with-a-healthy-dividend-yield/4121230048
- Published: 2025-12-11T11:18:52+00:00
- Author: Madison Wilson

National Research Corporation (NRC), a prominent player in the healthcare sector,
stands out in the health information services industry with its specialized focus
on analytics and insights for enhancing patient and employee experiences. Headquartered
in Lincoln, Nebraska, the company has built a reputation for delivering subscription-
based solutions that are integral to healthcare organizations striving to improve
service quality and operational efficiency.

Despite a modest market capitalization of $390.35 million, NRC’s financial metrics
present a mixed picture for potential investors. The stock is currently trading 
at $16.925, nearing the higher end of its 52-week range between $10.13 and $19.08.
This suggests a significant recovery and resilience in its stock price, although
the lack of detailed valuation metrics such as P/E, PEG, and Price/Sales ratios 
may deter some investors seeking a comprehensive financial analysis.

One of the most striking features of NRC’s financial performance is its exceptional
Return on Equity (ROE) of 66.87%. Such a high ROE indicates that the company is 
highly efficient in generating profits from its equity base, a positive sign for
investors looking for strong management performance and value creation. However,
the company’s revenue growth has declined by 3.40%, signaling potential challenges
in maintaining its market position or expanding its client base.

NRC’s earnings per share (EPS) stand at 0.71, and the company generates a free cash
flow of $7,574,500.00, underscoring its ability to maintain operations without external
financing. This cash flow strength supports NRC’s ability to sustain its dividend
payments, which yield a respectable 3.07%. With a payout ratio of 67.61%, the dividend
appears secure, providing a steady income stream for dividend-focused investors.

In terms of market sentiment and technical indicators, NRC appears to be in a bearish
phase, as indicated by its RSI (14) of 32.55, which is approaching oversold territory.
The stock’s current price is above both its 50-day and 200-day moving averages, 
priced at $14.12 and $14.26 respectively, suggesting potential upward momentum if
market conditions improve.

Notably, there are no analyst ratings or target price ranges available for NRC, 
which may reflect a lack of coverage or visibility in the broader market. This absence
of professional recommendations might pose a challenge for investors who rely on
analyst insights for decision-making.

NRC’s diverse portfolio of solutions, including the innovative Huey AI engine for
human understanding, positions the company well in the evolving landscape of healthcare
experience management. Its offerings cater to critical areas such as patient and
employee engagement, reputation management, and consumer experience, providing a
comprehensive suite of tools for healthcare organizations to enhance their service
delivery.

For investors considering NRC, the company’s strong ROE and attractive dividend 
yield may serve as compelling factors. However, the lack of detailed valuation metrics
and the recent decline in revenue growth warrant a cautious approach. Keeping an
eye on market trends and NRC’s ability to innovate and capture new opportunities
in the healthcare sector will be crucial for assessing its long-term investment 
potential.

Share on:
